JP2014528486A - Ｒｘｒアゴニスト化合物および方法 - Google Patents

Ｒｘｒアゴニスト化合物および方法 Download PDF

Info

Publication number
JP2014528486A
JP2014528486A JP2014535977A JP2014535977A JP2014528486A JP 2014528486 A JP2014528486 A JP 2014528486A JP 2014535977 A JP2014535977 A JP 2014535977A JP 2014535977 A JP2014535977 A JP 2014535977A JP 2014528486 A JP2014528486 A JP 2014528486A
Authority
JP
Japan
Prior art keywords
alkyl
dione
benzyl
thiazolidine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014535977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528486A5 (https=
Inventor
イー． ランドレス，ゲーリー
イー． ランドレス，ゲーリー
Original Assignee
ケース ウエスタン リザーブ ユニバーシティ
ケース ウエスタン リザーブ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケース ウエスタン リザーブ ユニバーシティ, ケース ウエスタン リザーブ ユニバーシティ filed Critical ケース ウエスタン リザーブ ユニバーシティ
Publication of JP2014528486A publication Critical patent/JP2014528486A/ja
Publication of JP2014528486A5 publication Critical patent/JP2014528486A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014535977A 2011-10-13 2012-10-15 Ｒｘｒアゴニスト化合物および方法 Pending JP2014528486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546777P 2011-10-13 2011-10-13
US61/546,777 2011-10-13
PCT/US2012/060262 WO2013056232A2 (en) 2011-10-13 2012-10-15 Rxr agonists compounds and methods

Publications (2)

Publication Number Publication Date
JP2014528486A true JP2014528486A (ja) 2014-10-27
JP2014528486A5 JP2014528486A5 (https=) 2015-12-03

Family

ID=48082779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535977A Pending JP2014528486A (ja) 2011-10-13 2012-10-15 Ｒｘｒアゴニスト化合物および方法

Country Status (4)

Country Link
US (1) US20140235676A1 (https=)
EP (1) EP2766018A4 (https=)
JP (1) JP2014528486A (https=)
WO (1) WO2013056232A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526503A (ja) * 2018-03-01 2021-10-07 ディージェイ セラピューティクス エルエルシー ベキサロテン誘導体および癌の治療におけるその使用

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316583A (zh) 2005-09-30 2008-12-03 生命医药公司 用特异性rxr激动剂治疗癌症
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2013090616A1 (en) 2011-12-13 2013-06-20 Io Therapeutics, Inc. Autoimmune disorder treatment using rxr agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
SG11201408284VA (en) * 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
US9550775B2 (en) 2013-03-14 2017-01-24 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
WO2015109318A2 (en) * 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
WO2015187850A2 (en) * 2014-06-03 2015-12-10 Duke University Compounds and methods for treatment of ocular disorders
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
CN104490867A (zh) * 2014-12-03 2015-04-08 沈阳药科大学 苯甲酸衍生物在制备抗血管新生药物中的用途
WO2016153949A1 (en) * 2015-03-20 2016-09-29 Deuterx, Llc 5-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using same
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN108290881B (zh) 2015-09-28 2021-12-07 健泰科生物技术公司 治疗性化合物和其使用方法
CN116077626A (zh) 2015-10-31 2023-05-09 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
KR102605349B1 (ko) 2016-03-10 2023-11-22 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
US10835507B2 (en) * 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
AU2017347549A1 (en) 2016-10-17 2019-05-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
CN108434116B (zh) * 2017-02-16 2021-05-11 人福普克药业（武汉）有限公司 贝萨罗汀软胶囊及其制备方法
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US11613517B2 (en) 2018-03-02 2023-03-28 Oregon Health & Science University Amide prodrugs of small molecule nuclear receptor modulators
WO2019191702A1 (en) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Substituted hydro-pyrido-azines as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020180624A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US12466781B2 (en) 2019-11-29 2025-11-11 Autobahn Therapeutics, Inc. Thyromimetics
US12590072B2 (en) 2020-06-17 2026-03-31 Autobahn Therapeutics, Inc. Thyromimetics
WO2021257851A1 (en) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
JP2002518318A (ja) * 1998-06-19 2002-06-25 アールティーピー・ファーマ・インコーポレーテッド 水に溶けない化合物のサブミクロン粒子を生成させる方法
JP2004518652A (ja) * 2000-12-18 2004-06-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 新規治療
JP2007503399A (ja) * 2003-08-26 2007-02-22 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント 生物活性化合物の粒子サイズの低減
JP2009084250A (ja) * 2007-10-02 2009-04-23 Hamamatsu Photonics Kk 固体組成物、微粒子、微粒子分散液、および、これらの製造方法
WO2011006157A2 (en) * 2009-07-10 2011-01-13 Case Western Reserve University Rxr agonist compounds and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195716T1 (de) * 1992-04-22 2000-09-15 Ligand Pharm Inc Retinoid-x rezeptor selektive verbindungen
EP1478384A2 (en) * 2001-06-11 2004-11-24 Ludwig Institute For Cancer Research Method for increasing the survival of dopamine secreting cells
US20040092589A1 (en) * 2002-06-21 2004-05-13 Liisa Neumann Use of retinoic acid for treatment of autism
US20050003998A1 (en) * 2002-08-15 2005-01-06 Goran Bertilsson Therapeutic use of selective LXR modulators
WO2007104030A1 (en) * 2006-03-08 2007-09-13 Kinemed, Inc. Retinoids and related compounds for the treatment of neuroinflammatory conditions, diseases and disorders
US9132170B2 (en) * 2011-07-29 2015-09-15 Case Western Reserve University Compositions and methods for treating cognitive deficits

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518318A (ja) * 1998-06-19 2002-06-25 アールティーピー・ファーマ・インコーポレーテッド 水に溶けない化合物のサブミクロン粒子を生成させる方法
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
JP2004518652A (ja) * 2000-12-18 2004-06-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 新規治療
JP2007503399A (ja) * 2003-08-26 2007-02-22 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント 生物活性化合物の粒子サイズの低減
JP2009084250A (ja) * 2007-10-02 2009-04-23 Hamamatsu Photonics Kk 固体組成物、微粒子、微粒子分散液、および、これらの製造方法
WO2011006157A2 (en) * 2009-07-10 2011-01-13 Case Western Reserve University Rxr agonist compounds and methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAIN PROTECTION IN SCHIZOPHRENIA, MOOD AND COGNITIVE DISORDERS, JPN6016030141, 2010, pages 343 - 395, ISSN: 0003374541 *
CLINICAL NEUROPHARMACOLOGY, vol. 31, no. 1, JPN6016030138, 2008, pages 25 - 33, ISSN: 0003374540 *
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. Vol.20, Suppl. 3, JPN6016030135, 2010, pages 187, ISSN: 0003374542 *
XPHARM: THE COMPREHENSIVE PHARMACOLOGY REFERENCE, JPN6016030143, 2007, pages 1 - 4, ISSN: 0003374543 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526503A (ja) * 2018-03-01 2021-10-07 ディージェイ セラピューティクス エルエルシー ベキサロテン誘導体および癌の治療におけるその使用
JP7296643B2 (ja) 2018-03-01 2023-06-23 ディージェイ セラピューティクス エルエルシー ベキサロテン誘導体および癌の治療におけるその使用
US12338214B2 (en) 2018-03-01 2025-06-24 DJ Therapeutics LLC Bexarotene derivatives and their use in treating cancer

Also Published As

Publication number Publication date
WO2013056232A2 (en) 2013-04-18
EP2766018A4 (en) 2015-02-25
EP2766018A2 (en) 2014-08-20
US20140235676A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
JP2014528486A (ja) Ｒｘｒアゴニスト化合物および方法
JP5902619B2 (ja) Ｒｘｒアゴニスト化合物および方法
US12083107B2 (en) Pharmaceutical compositions comprising glitazones and Nrf2 activators
JP2021008473A (ja) 細胞生存率を向上させるための組成物およびその使用方法
JP2010504338A (ja) 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール
TW202114679A (zh) 治療特發性肺纖維化的方法
JP2010507672A (ja) アルツハイマー病を治療するための方法および組み合わせ治療
JP2008515778A (ja) 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療
JP7695246B2 (ja) アルツハイマー病の治療のための化合物
JP2021518347A (ja) ペルオキシソーム増殖因子活性化受容体アルファのアゴニストおよび使用方法
US12364676B2 (en) Compositions and methods for treating retinopathy
WO2023134732A1 (en) Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids
CN102365269A (zh) 用于治疗认知缺损的新药物
JP2008502607A (ja) 痴呆の予防および治療におけるＬ−ｎ−ブチルフタリドの適用
JP5714524B2 (ja) 痴呆の予防および治療におけるＬ−ｎ−ブチルフタリドの適用
OA21243A (en) Compounds for treatment of alzheimer's disease.
EA048112B1 (ru) Соединения для лечения болезни альцгеймера

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170418